Background. Omega-3 fatty acids supplements lower triglyceride (TG) levels in adults; little pediatric information is available. We evaluated their effect in hypertriglyceridemic adolescents. Methods. Twenty-five patients aged 10 to 19 years with TG levels 150 to 1000 mg/dL were randomized to 6 months double-blind trial of Lovaza (~3360 mg docosahexaenoic acid + eicosapentaenoic acid per day) versus placebo. Results. Baseline mean TG levels were 227 mg/dL (standard deviation = 49). TG levels declined at 3 months in the Lovaza group by 54 ± 27 mg/dL (mean ± standard error; P = .02) and by 34 ± 26 mg/dL (P = .16) in the placebo group. The difference in TG lowering between groups was not significant (P = .52). There were no between-group differences in endothelial function, blood pressure, body mass index, C-reactive protein, or side effects. Conclusions. High-dose omega-3 fatty acid supplements are well tolerated in adolescents. However, declines in TG levels did not differ significantly from Placebo in this small study.
SarwarNDaneshJEiriksdottirG. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-458.
2.
HaimMBenderlyMBoykoV; Bezafibrate Infarction Prevention (BIP) Study Group. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a bezafibrate infarction prevention substudy. Coron Artery Dis. 2006;17:455-461.
3.
ToskesPP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19:783-791.
4.
WangCHarrisWSChungM. N-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:5-17.
5.
BucherHCHengstlerPSchindlerCMeierG. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.
6.
HarrisWSGinsbergHNArunakulN. Safety and efficacy of omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391.
7.
BalkEChungMLichtensteinA. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). 2004;(93):1-6.
8.
KotwalSJunMSullivanDPerkovicVNealB. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808-818.
9.
MozaffarianDLemaitreRNKingIB. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med. 2013;158:515-525.
10.
De CaterinaR. N-3 fatty acids in cardiovascular disease. N Engl J Med. 2011;364:2439-2450.
11.
Risk and Prevention Study Collaborative Group, RoncaglioniMCTombesiMAvanziniF. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800-1808.
12.
KitBKCarrollMDLacherDASorliePDDeJesusJMOgdenC. Trends in serum lipids among us youths aged 6 to 19 years, 1988-2010. JAMA. 2012;308:591-600.
13.
de FerrantiSDCreanSCotterJBoydDOsganianSK. Hypertriglyceridemia in a pediatric referral practice: experience with 300 patients. Clin Pediatr (Phila). 2011;50:297-307.
14.
BodenWEProbstfieldJLAndersonT. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
15.
SuhHSHayJWJohnsonKADoctorJN. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf. 2012;21:470-484.
16.
BuyukcelikMAnaratABayazitAK. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr. 2002;44:40-44.
17.
ChicaudPDemangeJDrouinPDebryG. Action of fenofibrate in hypercholesterolemic children: 18-month follow-up [in French]. Presse Med. 1984;13:417-419.
18.
SteinmetzJMorinCPanekESiestGDrouinP. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta. 1981;112:43-53
19.
CollettiRBNeufeldEJRoffNKMcAuliffeTLBakerALNewburgerJW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92:78-82.
20.
EnglerMMEnglerMBMalloyMJPaulSMKulkarniKRMietus-SnyderML. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the early study). Am J Cardiol. 2005;95:869-871.
21.
PedersenMHMolgaardCHellgrenLIMatthiessenJHolstJJLauritzenL. The effect of dietary fish oil in addition to lifestyle counselling on lipid oxidation and body composition in slightly overweight teenage boys. J Nutr Metab. 2011;2011:348368.
22.
NobiliVBedogniGAlisiA. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350-353.
23.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
24.
RamsayJEFerrellWRCrawfordLWallaceAMGreerIASattarN. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab. 2002;87:4231-4237.
25.
JenkinsDJWoleverTMJenkinsAL. The glycaemic index of foods tested in diabetic patients: a new basis for carbohydrate exchange favouring the use of legumes. Diabetologia. 1983;24:257-264.
26.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
27.
SchwartzBJacobsDRJrMoranASteinbergerJHongCPSinaikoAR. Measurement of insulin sensitivity in children: comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care. 2008;31:783-788.
28.
Selamet TierneyESNewburgerJWGauvreauK. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009;154:901-905.
29.
KuvinJTPatelARSlineyKA. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168-174.
30.
BonettiPOPumperGMHiganoSTHolmesDRJrKuvinJTLermanA. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137-2141.
31.
Fish oil supplements. Med Lett Drugs Ther. 2006;48:59-60.
32.
CarpentierYAPortoisLMalaisseWJ. N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr. 2006;83(6 suppl):1499S-1504S.
33.
DelarueJCouetCCohenRBrechotJFAntoineJMLamisseF. Effects of fish oil on metabolic responses to oral fructose and glucose loads in healthy humans. Am J Physiol. 1996;270:E353-E362
34.
HarrisWSRothrockDWFanningA. Fish oils in hypertriglyceridemia: a dose-response study. Am J Clin Nutr. 1990;51:399-406.
35.
SchmidtEBKristensenSDDe CaterinaRIllingworthDR. The effects of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients with hyperlipidemia. Atherosclerosis. 1993;103:107-121.
PischonTHankinsonSEHotamisligilGSRifaiNWillettWCRimmEB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155-160.
38.
BoakLChin-DustingJP. Hypercholesterolemia and endothelium dysfunction: role of dietary supplementation as vascular protective agents. Curr Vasc Pharmacol. 2004;2:45-52.
39.
GoodfellowJBellamyMFRamseyMWJonesCJLewisMJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000;35:265-270.
40.
CalderPC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 suppl):1505S-1519S
41.
MoriTABeilinLJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461-467.
42.
SatohNShimatsuAKotaniK. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30:144-146.
43.
BerensonGS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90:3L-7L.
44.
MorrisonJAGlueckCJWangP. Childhood risk factors predict cardiovascular disease, impaired fasting glucose plus type 2 diabetes mellitus, and high blood pressure 26 years later at a mean age of 38 years: the Princeton-Lipid Research Clinics Follow-up Study. Metabolism. 2012;61:531-541.
45.
SchrottHGClarkeWRAbrahamsPWiebeDALauerRM. Coronary artery disease mortality in relatives of hypertriglyceridemic school children: the Muscatine study. Circulation. 1982;65:300-305.
